PCYT1A and diffuse large B-cell lymphoma: In patients with diffuse large B-cell lymphoma (DLBCL), elevated PCYT1A expression, accompanied by increased MYC levels and decreased serum PC, correlates with a higher international prognostic index risk classification, suggesting that co-expression of MYC and PCYT1A may serve as a biomarker for disease progression (223).